Study of the antioxidant action of two analgesic compounds, morphine and propofol, on the activity of MPO and HRP

Although acute inflammation can efficiently be treated, the treatment of chronic inflammatory pathologies is still a challenge to rise. As marker of inflammation, the enzyme Myeloperoxidase (MPO) is a choice target for the establishment of a treatment. Indeed, the uncontrolled release in the extracellular medium of MPO, marker of inflammation, along with the release of ROS, causes severe damages on biological tissues. The modulation of the enzyme activity, by an inhibitor, might constitute an approach to treat excessive inflammation. An interesting pathway is to give a second life to clinical-used molecules, presenting antioxidant and anti-inflammatory properties. According to several studies, morphine and propofol (PPF), which are already known for their analgesic and anesthetic properties, present an antioxidant activity. Therefore, these reducing molecule can potentially pretend to be MPO inhibitors.